News

ICYMI, some of the content featured this week includes articles about a new diversity and equity initiative from Skinbetter Science and Allergan Aesthetics, patient sunscreen savviness, skin of color patients lacking in phase 3 psoriasis trials, plus more.

In this episode, Candrice Heath, M.D., sits down to discuss her recent presentation at the 2020 Skin of Color Update about clinical pearls for kids, tweens and teens with skin of color. Dr. Heath also explains the most common skin conditions for this patient group, treatment challenges, and much more.

Merck announces positive results from its phase 2b trial evaluating sonelokinab, an investigational anti-IL-17 A/F nanobody, in adult patients with moderate-to-severe chronic plaque psoriasis.

Allergan Aesthetics and Skinbetter Science announce the launch of The DREAM Initiative, aimed at improving racial diversity and equity in the aesthetics field.

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for Sol-Gel’s Epsolay, a 5% microencapsulated benzoyl peroxide cream for the treatment of inflammatory lesions of rosacea or papulopustular rosacea.

Novartis announces their phase 3 study investigating spartalizumab (PDR001) in combination with dabrafenib (Tafinlar) and trametinib (Mekinist) failed to meet its primary endpoint.

This week’s edition of The Mainstream Patient features stories about the difference between sunblock and sunscreen, lip dryness after getting filler, stress and psoriasis, the issues around skin lightening products, plus more.

ICYMI, some of the content featured this week includes a video series on dermatologic care during COVID-19 and how the pandemic could be a catalyst for expansion into underserved populations, a look at when is the best time for follow-ups with patients after Mohs surgery, a deeper look at the new “clean” cosmetics trend, plus more.

A recent study from the University of Missouri School of Medicine investigates when is the best time to make post-operative phone calls to patients following Mohs micrographic surgeries.

Menlo Therapeutics has officially changed its name to VYNE Therapeutics.

Castle Biosciences announces the launch of DecisionDx-SCC, a prognostic gene expression profile test for patients with high-risk cutaneous squamous cell carcinoma (cSCC).

A study recently published in the Journal of the American Academy of Dermatology reveals patients with chronic inflammatory skin diseases also have an increased risk for herpes zoster (shingles), which has the possibility to lead to extended hospitalizations.

"Clean" skincare has become a popular trend. A preference for products without certain ingredients is fine if the products make patients feel better without making their skin worse, one expert says.

This week’s edition of The Mainstream Patient features stories about the difference between cold sores and acne, glycerin in skincare, psoriasis and its effect on mental health, how to avoid tech neck, plus more.

ICYMI, some of the content featured this week includes articles about a new adapalene gel for acne vulgaris, if preservatives like parabens are actually safe in cosmetics, characteristics that can help distinguish facial hyperpigmentation disorders, valuable information about vitiligo treatment with expert Seemal R. Desai, M.D., FAAD, plus more.

In this episode, UIC medical students Kayla Clark and Gina Alvarado Jones, along with UIC Dermatology Department Head Maria Tsoukas, M.D. Ph.D., discuss their recently published analysis in JAAD, which takes a look at skin of color representation in medical education.

MC2 Therapeutics and EPI Health announce they have entered into a collaboration agreement for the commercialization of calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064% (Wynzora Cream), a newly U.S. FDA-approved topical treatment for plaque psoriasis in adults.

Alembic Pharmaceuticals announces the launch of their bioequivalent and therapeutically equivalent product to Differin Gel 0.3% (Galderma), Adapalene Gel USP 0.3%, a topical retinoid for the treatment of acne vulgaris in patients 12 years and older.

Vitiligo can be psychologically devastating for patients. Expert Seemal R. Desai, M.D., FAAD, shares how recent advances in vitiligo treatment offer hope to patients impacted by the disease.

While several employees wanted to wear masks upon his office reopening, Dr. Covid reminded them that their state governor and city mayor did not require their use. Now an employee has contracted COVID-19 from a patient and has filed a complaint with the Occupational Safety and Health Administration. Should he be concerned?

This week’s edition of The Mainstream Patient features stories about a newly approved acne treatment, strawberry legs, coconut oil in skincare, if your acne might possibly be rosacea, plus more

Subtypes such as confetti vitiligo and trichrome vitiligo can be signs of unstable active disease, says expert Seemal R. Desai, M.D., FAAD.

ICYMI, some of the content featured this week includes articles about emerging options for high-risk melanoma, a new FDA-approved topical androgen receptor inhibitor for treatment of acne vulgaris, a glimpse into the world of vitiligo treatment with expert Seemal R. Desai, M.D., FAAD, plus more.

Clascoterone cream 1% (Winlevi, Cassiopea), a first-in-class androgen receptor inhibitor, has been approved by the U.S. FDA for treatment of acne vulgaris in patients 12 years and older.

Expert Seemal R. Desai, M.D., FAAD, highlights new therapeutics that may impact the future of vitiligo management, a topic he discussed at the AAD Virtual Meeting Experience (VMX) in June.

Antioxidants can be a valuable part of your vitiligo therapeutic armamentarium, says expert Seemal R. Desai, M.D., FAAD.

Dermavant announces positive results from its two identical phase 3 trials investigating tapinarof cream 1% for treatment of plaque psoriasis in adult patients.

Manipulating the microbiome has been shown to impact conditions including acne, atopic dermatitis (AD), autoimmune diseases and melanoma. While there are many clinical trials now in progress, safety and efficacy have not yet been proven.

Eli Lilly’s mirikizumab demonstrates superiority over secukinumab (Cosentyx, Novartis) as a treatment for moderate-to-severe plaque psoriasis, according to recently released results from the OASIS-2 study.